Moderna’s stock doubles on promising cancer-vaccine results
The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.
We haven't written up this one. MarketWatch Top has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Moderna’s stock doubles on promising cancer-vaccine results marketwatch.com
